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In this podcast, we talk to Professor Michael O’Donovan about the latest genetic advances in schizophrenia based
on research data from the Schizophrenia Working Group of the Psychiatric Genomics Consortium. Functional and
prediction studies from the identified genetic loci are described together with future directions in psychiatric
genetics and its interplay with the environment.
The podcast for this interview is available at http://media.biomedcentral.com/content/movies/supplementary/
s12916-015-0417-1-s1.mp3Introduction
Professor Michael O’Donovan is a psychiatrist who under-
went doctoral scientific training courtesy of the Medical
Research Council (MRC) Training and Travelling
Fellowship schemes. He works in the Division of
Psychological Medicine and Clinical Neurosciences where
he is Professor of Psychiatric Genetics and Deputy
Director of the MRC Centre for Neuropsychiatric Genet-
ics and Genomics. His clinical work is at the Cardiff and
Vale University Health Board. He has a broad interest in
the molecular genetics and neurobiology of mental disor-
ders, and, specifically with reference to the contents of the
podcast, is the Lead for the Schizophrenia Group of the
Psychiatric Genomics Consortium, a group of over 300
researchers from more than 35 countries (Fig. 1).
The podcast for this interview is available at http://
media.biomedcentral.com/content/movies/supplementary/
s12916-015-0417-1-s1.mp3 (Podcast Q & A: Additional
file 1).Edited transcript
1. You are a leading expert in the molecular genetics of
major psychiatric disorders including schizophrenia. Can you
explain why you decided to specialise in this particular area?
During my medical training, I found psychiatry to be an
interesting subject, which is why after completingCorrespondence: odonovanmc@cardiff.ac.uk
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that time, I became very interested in schizophrenia. It was
clear that people did not know a lot about what caused
schizophrenia, but that genetics was a pretty promising
clue. That, together with some inspiration from Professor
Peter McGuffin, who was Head of Department in Cardiff
when I was a Lecturer, and later Professor Mike Owen, got
me into genetics. Since my early training in the subject, the
techniques of molecular genetics constantly evolved until
finally, after a very long slog, it has been possible to actually
use the principles of genetics to make some discoveries in
this complicated field. So, the usual mixture of interest,
luck, and being in the right place at the right time is what
got me into the genetics of psychiatric disorders in general
and schizophrenia in particular.
2. This has resulted in several major findings in the field.
Recently, you have been the lead author on the largest
molecular genetics study of schizophrenia that was
published in Nature last year [1]. This study came about
as a result of the Schizophrenia Working Group of the
Psychiatric Genomics Consortium. Can you describe why
this consortium was formed and tell us what genotype
data it included?
Over the last 20 years, researchers have been working
initially on their own samples, which were often a hun-
dred cases and a hundred controls, or so. By 2001, even
the larger samples increased to only about 500 cases and
500 controls. At the same time, it became increasingly
clear from developments that were taking place in theticle distributed under the terms of the Creative Commons Attribution License
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betes, that the effect sizes of risk alleles we were looking
for, or the amount of population risk that any one gen-
etic variation contributed to, was likely to be small. As a
result, people began to recognise that we needed sample
sizes well above those that individual groups were study-
ing. So in the mid-2000s, consortia were formed.
I was part of the International Schizophrenia
Consortium, and even then the sample sizes were a few
thousand cases and a few thousand controls. After the
Wellcome Trust Case Control Consortium Study of Seven
Common Diseases, it was pretty clear that even these sam-
ples were not powerful enough to make much of a dent in
the genetics of the disorder, and that turned out to be true
when those consortia analysed their results. So, the con-
sortia themselves started to amalgamate; people in these
smaller consortia began to reach out to everyone they
knew who was working in the field to try and bring the
samples together, with the hope of getting a decent-sized
sample with power to make clear and unambiguous find-
ings. Pat Sullivan was a major driving force here in psych-
iatry in general, and within schizophrenia, Pablo Gejman
led the first Psychiatric Genomics Consortium (PGC)
study. It has really been, once again, a process of evolution;
people have recognised that the sample size was a problem,
and they have banded together in increasingly large num-
bers to contribute their samples and their genetic data.For this particular study, the vast majority of the investi-
gators have made what we call the ’individual genotypes’
available to the consortium. Each group mostly performed
their own genome-wide association studies (GWASs) and
they contributed the individual level genotypes into a cen-
tral data repository in the Netherlands. This included
groups from 34 different countries across the globe. As
well as Europe and North America, it also included a
number of groups from Australia and from Asia, and in
particular Japan, Singapore, and some groups with
Chinese samples. It was truly an international collabor-
ation - and it’s getting bigger.
We undertook a meta-analysis of all of these raw indi-
vidual genotype data, and then at the end we sought repli-
cation from a separate consortium that for legal reasons
could not contribute all of its data. That consortium was
led by Decode Genetics in Iceland, and they contributed
summary statistics in a format that allows us to combine
their results with our primary GWAS results.3. The Schizophrenia Working Group of the consortium
really enabled a large number of cases and controls in
the meta-analysis. Could you briefly describe the findings
of the study?
I expect that people may be aware that in these surveys
of essentially the whole of the genome for common gen-
etic variations, we require very stringent statistical
thresholds to recognise a finding as being very likely a
true positive rather than a statistical chance aberration.
We found over 120 such associations that surpassed this
threshold, which means that there is a very, very strong
chance that these things are true. When we distilled that
down and accounted for multiple associations to the
same genomic region, we found that we had 108 inde-
pendent findings. So, there were 108 physically distinct
chromosome regions associated with schizophrenia.
Each of those regions, in turn, contains one or often
more than one gene, so the next task is to try and dis-
cover how association points to change in gene function.
To explain the actual findings, first of all I would like to
make an important caveat for those people who are not
geneticists: an association does not pinpoint a gene. An as-
sociation points to a region of a chromosome. As I said a
moment ago, some associated regions contain multiple
genes that could be driving this association signal. Some
contain apparently only one gene that could be driving the
signal. However, there are as yet unrecognised functional
elements in the genome. Thus, it is actually possible, for
example, that if we find an association to a region that
contains only one gene, it might be a functional element
that drives changes in a gene some distance away that we
are not yet aware of. However, in general it seems to be a
valid assumption that the relevant genes that are driving
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variant that shows association.
With that important caveat in mind, what we actually
found was that, as is generally the case in studies like
this in other diseases, the associations were to regions
containing a whole host of genes that one would never
particularly suspect to be involved in schizophrenia. For
many of these genes, we do not even have the faintest
clue about their function.
We also found a number of associations that appear to
point to historical genetic favourites. Schizophrenia, being
a somewhat enigmatic disorder in terms of its underlying
biology, has been linked to many hypotheses about how
the disorder is caused. Some of the leading hypotheses
concern alteration in dopamine function, and particularly
a receptor called dopamine D2 receptor (DRD2), which is
the target of all antipsychotic drugs. We found an associ-
ation that would probably implicate that gene as being
involved in the basic aetiology of schizophrenia. We add-
itionally found associations in and around a rather large
number of genes that affect glutamate function, which is
also one of the more important longstanding neurochem-
ical hypotheses of schizophrenia.
Thus, we found a range of findings that pointed to
some old hypotheses being at least in part relevant to
the pathophysiology of schizophrenia. However, most of
the findings point to the possibility of novel genes. Really
the work is just beginning to try and figure out how
those associations may relate to the pathophysiology of
the disorder.4. To explore the regulatory nature of the identified
genetic variants, they were tested in different cell lines
and tissues. What were the results of these functional
investigations?
One way of trying to pursue how genetic associations
might relate to broad areas of biology is to do what are
called gene set analyses, pathway analyses, or network
analyses, where one takes all the findings and tries to
link them to groupings of genes that are perhaps
expressed in certain tissues or are involved in certain
biological processes.
One of the approaches that we took was to use publicly
available Encyclopaedia of DNA Elements (ENCODE)
data. ENCODE is studying the regulatory elements of the
human genome. What we did was to extract from that
data DNA regulatory elements that appear to be most ac-
tive in particular tissues and cells, and test whether the
genetic associations are enriched in and around those
regulatory elements. For example, is there an excess of as-
sociations around regulatory elements that appear to be
active in neurones or in lymphocytes or in the gut or in
the pancreas?In general, we found two main things using that ap-
proach. We found that gene regulatory elements that ap-
pear to be active in brain tissue and neuronal cell lines
were particularly enriched for schizophrenia associa-
tions, suggesting, as would have widely been expected,
that schizophrenia is in a substantial way a disorder of
the brain rather than a disorder of the gut or gut absorp-
tion or many of the other hypotheses that been voiced in
the history of schizophrenia but still persist.
One of the more intriguing novel findings was the en-
richment of association in regulatory elements that are
particularly active in a number of immune tissues. Again,
all this type of work always comes with an important cav-
eat. When we see enrichment of association signals in the
vicinity of regulatory elements that appear to be active in
immune tissues, what we are not yet sure of is whether
those regulatory elements are specific for immune tissues.
Could it be that those regulatory elements are also par-
ticularly active in the sorts of tissues that you would ex-
pect like the brain?
We did try to statistically allow for that, and it would
appear that there was an independent enrichment of the
association signal. Regulatory elements that we did not
find to be particularly active in the brain but were active
in these immune tissues were also enriched for signals.
However, there are a number of unanswered questions
at the moment including which genes are exactly af-
fected in the immune tissues. Do these genes only have
immune functions or do they have functions in the
brain? What change in function is indicated by an asso-
ciation? This is why, in our manuscript, we posed some
caution about the interpretation of the immune finding.
In some ways this was one of the more interesting re-
sults because, if it is true, it supports very longstanding
hypotheses that schizophrenia involves sub-optimal im-
mune responses, for example, excessive responses to infec-
tion or perhaps some forms of autoimmunity. However,
one does not want to jump too far in coming to that con-
clusion based purely upon genetic data.
5. Another finding was of overlap of the novel genetic
loci with de novo genetic mutations. Can you briefly
describe what that analysis showed?
This analysis was perhaps quite an unexpected finding
in many quarters. The background to this is that, in par-
allel to these common genetic variant studies that have
been taking place in schizophrenia, we and others have
also been studying rare genetic variation in the disorder
in the form of copy number variation, but more recently
through DNA sequencing looking for point mutations.
We have studied both de novo copy number variants
in schizophrenia and de novo point variations in schizo-
phrenia. It is now clear that these new mutations - ones
that occur in a person but not in either of his or her
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schizophrenia. It is not a high proportion, but these
may be important mutations because in theory their ef-
fect sizes might be much bigger than these common
genetic variants that we have been discussing which in-
dividually have very small effect sizes.
Having identified genes with these very rare new muta-
tions in our earlier work, we now looked to see if these
cluster more than one would expect in the same regions
that are showing genome-wide association. We found evi-
dence that they do. Moreover, we also showed that genes
that show similar types of de novo mutations for other
neurodevelopmental disorders also tend to cluster in the
schizophrenia associated regions. This supports the broad
hypothesis that many of the neurodevelopmental disorders
are, to a certain extent, aetiologically linked. Here I am re-
ferring specifically to intellectual disability and to autism
spectrum disorder, though the evidence is wider and in-
cludes for example ADHD as well. This is further evidence
that there is some kind of commonality between these dis-
orders. I think of them as sharing part of their aetiology,
not all, and for the bit in common, they differ to a certain
extent by the severity of the mutation type.
The other important implication of that finding of
overlap is that one of the criticisms that people levy at
researchers who are studying rare genetic variations is:
“This is some kind of weird subtype of the disorder that
does not really have any relevance to the disorder as a
whole in the general population.” The modest degree of
convergence between rare genetic variation and com-
mon genetic variation suggests that the findings that one
might make from these kinds of rarer, bigger effect mu-
tations will have biological relevance for the general
population of people with schizophrenia. The reason
why this is important is that, in many respects, when
one is doing follow-up functional studies (modelling
them in cell lines or in animals) it is easier to do model-
ling with the rare genetic variation that tends to have
larger effects on the disorder, compared with those with
rather weak genetic effects.
6. An additional part of the study determined the risk of
the profile scores to predict the presence or absence of
the disorder. Can you briefly explain how the genetic
data obtained could predict case control status?
Although we have detected quite a large number of associ-
ations, they are the tip of the iceberg. Say we don’t just
take these very stringently associated genetic variants but
rather go down the list to more weakly associated genetic
variants, those that we call ’sub-threshold’ associated.
These met some level of significance, but as we go further
down the list of significance, we become less confident
that any given individual allele is associated with the dis-
ease. Nevertheless, the theory is that those that show someevidence for association should be relatively enriched for
true associations, even though as we go down the list, for
any true association, we drag in many more false ones.
In this way, we consider all alleles that are more sig-
nificant than some nominal threshold as ’potential risk’
alleles. We derive them from one dataset; let’s say there
are 10,000 of these alleles that surpass some kind of stat-
istical threshold. Subsequently, in an independent sam-
ple, and simplifying this procedure to some extent, one
simply counts up how many of these risk alleles each
person carries. The prediction is that cases from a differ-
ent study will have a higher number of these risk alleles
than the controls do. What we call the risk profile score
is a weighted average of the number of these risk alleles
carried. That this approach could statistically differenti-
ate between cases and controls was shown by a study
that was published in Nature by the International
Schizophrenia Consortium. However, in the early days
the predictive power enabled statistical differentiation
between cases and controls, but the sensitivity and speci-
ficity were extremely poor. However, as the genome-
wide association studies became larger, the power to
achieve this discrimination has improved.
So the principle works certainly, but it is important to
note in practice that we still cannot use this for a clinical
diagnosis. Although we have high statistical significance -
we can obtain very, very small P-values concerning group
differences between cases and controls - when it comes to
looking at an individual person, although cases have on
average a higher score than the controls, many of the con-
trols have scores higher than many of the cases. In other
words, the score distribution from cases overlaps substan-
tially with the score distribution from controls, and as an
upshot, we cannot confidently predict who is a case and
who is a control based only on their polygenic score.
What we can do in a research setting is screen large
population samples which have GWAS data and find
people who are at relatively higher risk for schizophre-
nia, even though the vast majority of them will develop
schizophrenia, and at the other end of the score distribu-
tion, people who are at relatively low genetic risk for the
disorder, even though a small proportion of them will in
fact develop the disorder. We can then start doing inter-
esting studies about how those two populations differ in
terms of biology to try to find out what it is about brain
function that relates to high and low risk. The profile
scores are useful in a research setting, but they are of no
current value in a clinical setting.
7. Can you describe the future directions in the field of
psychiatric genetics and how it will be influenced by the
interplay with the environment?
In principle, the simplest thing that we and others are try-
ing to do is increase the sample sizes, because although
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to be done. The aim of the Psychiatrics Genomics Consor-
tium is, over the next four years perhaps, to try and get
GWAS data on 100,000 cases instead of the current num-
ber in the mid-30,000s. Thus, we are looking for more
power and more findings.
It is also important to try and achieve much better
functional interpretation of the common genetic find-
ings. That will require better functional annotation of
the genome, in terms of which genetic variants regu-
late genes in which cell types and in which areas of the
brain at what developmental times including foetal life.
A lot of background biology is required to try and
provide resources that allow us to interpret common
genetic findings.
We and others are also interested in trying to use the
common genetic findings and rare genetic results to sub-
classify the heterogeneous disorder into more homoge-
neous groups. So far, attempts to carve it up by symptom
pattern or age at onset, or in various other ways that one
might conceptualise, have not really produced convincing
results. The reason why we are trying to get more homo-
geneous populations of people with the disorder is that
such membership of distinct groups might be clinically
useful, for example, in trying to figure out why some treat-
ments work in some people but not in others, and in over-
all improving the treatment prospects.
There is also a lot of work going on in rare genetic
variation. Increasingly, people are adopting sequencing
approaches - initially exome sequencing as we have done
looking for de novo mutations, but over the next few
years we expect there to be larger samples that will be
analysed by whole genome sequencing. Here the object-
ive is that rare genetic variation contributes to some
genetic risk, although most of us do not believe that rare
genetic variation contributes to the majority of the gen-
etic risk. As I mentioned earlier on in this podcast, it is
easier to model the mutations in cells and animals and
thereby probe what kind of biological consequences gen-
etic variants have on cellular function and whole organ-
ism function, respectively.
Researchers are also interested in taking the genetic
findings and figuring out what kind of physiological
changes occur in people without the disorder. Perhaps
this can be indexed by observing changes in brain func-
tion using functional imaging techniques or varying
other methods for assaying brain function. Additionally
cognitive function can be determined in terms of meas-
uring brain performance. We in Cardiff, along with col-
leagues in London led by Shitij Kapur, are trying to use
various genetic profiling techniques to try and predict
who will and who will not respond to particular treat-
ment types. We regard the genetic findings really as an
infrastructure for a whole range of future investigations.It is impossible for me to predict or detail every single
way that this is likely to be exploited; the options are
almost boundless.
There is certainly an environmental contribution to
schizophrenia. We have some clues that perhaps peri-
natal infections or other forms of adverse challenges
during pregnancy and surrounding childbirth contribute.
There is evidence that very traumatic experiences in
childhood may contribute, and that in certain popula-
tions that migration, possibly as a result of stress or dis-
crimination, contributes to the disorder. Thus, there are
a range of clues about the environment. What is more
controversial is whether or not environmental exposures
in general increase your risk or only increase your risk
with a given genetic background. The latter is often re-
ferred to as ’gene-environment interaction’.
Environmental studies that include genetic data, and
genetic studies that include environmental data, are sub-
optimal at the moment. The power to detect so-called
gene-environment interactions is significantly less than
it is to identify the genetic effects in the first place, al-
though studies are proceeding to try and see how par-
ticular genes or whole genetic risk relates to drug abuse
in terms of dictating schizophrenia risk. In fact, I and
my colleagues, led by Jim van Os at the University of
Maastricht, have such a study funded by the European
Union. I expect that the main deliverables from that will
take several more years, because I suspect the sample
sizes are currently inadequate.
8. Where can I find out more?
See the reference list [1–10].
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